Valeant On Stronger Ground As It Readies For Allergan Showdown
This article was originally published in The Tan Sheet
Executive Summary
The Canadian pharma reported a strong third quarter and an improved debt position as it prepares for the December meeting with Allergan shareholders that could result in changes to the Botox maker’s board and acceptance of Valeant’s takeover offer.